<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396899</url>
  </required_header>
  <id_info>
    <org_study_id>02289</org_study_id>
    <nct_id>NCT04396899</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure</brief_title>
  <acronym>BioVAT-HF</acronym>
  <official_title>Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered&#xD;
      heart muscle (EHM), the proposed investigational medicinal product (IMP; designated&#xD;
      &quot;Biological Ventricular Assist Tissue&quot; or BioVAT), results in sustainable remuscularization&#xD;
      and biological enhancement of myocardial performance in the failing heart. EHM are&#xD;
      constructed from defined mixtures of induced pluripotent stem cell (iPSC)-derived&#xD;
      cardiomyocytes and stromal cells in a bovine collagen type I hydrogel. Comprehensive&#xD;
      preclinical testing confirmed the rationale for the clinical translation of the myocardial&#xD;
      remuscularization strategy by EHM implantation. The patient target population for EHM therapy&#xD;
      is patients suffering from advanced heart failure with reduced ejection fraction (HFrEF; EF:&#xD;
      ≤35%) and no realistic option for heart transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target heart wall thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Target heart wall thickness (HWT) as determined by high resolution echocardiography and/or CINE-mode MRI (17-segment model). Primary efficacy analyses are based on the changes in HWT between baseline and 2 weeks, 1 month, 3 months, 6 months and 12 months after implantation. To test for a time effect a one-way Repeated Measures ANOVA will be performed for the primary endpoint. In case of detecting a time effect this is followed by Dunnett-type pairwise comparisons to baseline using paired t-Tests. Due to the explorative character of the efficacy analysis testing will be performed at a 10% two-sided significance level. Mean differences will be reported along with 90% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart wall thickening fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Heart wall thickening fraction (HWTF) as determined by high resolution echocardiography and/or CINE-mode MRI (17-segment model). Primary efficacy analyses are based on the changes in HWTF between baseline and 2 weeks, 1 month, 3 months, 6 months and 12 months after implantation. To test for a time effect a one-way Repeated Measures ANOVA will be performed for the primary endpoint. In case of detecting a time effect this is followed by Dunnett-type pairwise comparisons to baseline using paired t-Tests. Due to the explorative character of the efficacy analysis testing will be performed at a 10% two-sided significance level. Mean differences will be reported along with 90% confidence intervals.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>EHM Implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive EHM implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EHM implantation</intervention_name>
    <description>Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF &lt;35%).</description>
    <arm_group_label>EHM Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HFrEF (EF ≤ 35%) as assessed by high-resolution echocardiography or MRI&#xD;
&#xD;
          2. No realistic chance or not eligible for heart transplantation&#xD;
&#xD;
          3. At least one hypo- or dyskinetic segment to demark the implant target area&#xD;
&#xD;
          4. Stable disease condition allowing for an elective left-lateral mini-thoracotomy (for&#xD;
             LV applications) or open-chest surgery (for RV applications) for a clinically&#xD;
             indicated intervention on the LV (e.g., coronary bypass surgery, valve repair) with&#xD;
             concomitant RV dysfunction, diagnosed using the Tricuspid Annular Plane Systolic&#xD;
             Excursion (TAPSE) index &lt;16 mm (Rudski et al. 2010).&#xD;
&#xD;
          5. 18-80 years of age&#xD;
&#xD;
          6. Previous implantation of an ICD or CRT-D with event recorder&#xD;
&#xD;
          7. New York Heart Association (NYHA) Class III or IV under optimal medical therapy&#xD;
&#xD;
          8. Willingness and ability to give written informed consent&#xD;
&#xD;
          9. Female subjects of childbearing potential must agree to use acceptable method(s) of&#xD;
             contraception for the full study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to immunosuppressive drugs (e.g. known history of unresolved cancer,&#xD;
             hepatitis B/C, HIV, HTLV1)&#xD;
&#xD;
          2. Alloimmunisation against EHM implant cells&#xD;
&#xD;
          3. Hypertrophic cardiomyopathy (HCM)&#xD;
&#xD;
          4. Terminal kidney failure (stage 4; GFR &lt;30 ml/min)&#xD;
&#xD;
          5. Terminal liver failure&#xD;
&#xD;
          6. Autoimmune disease&#xD;
&#xD;
          7. History of stroke&#xD;
&#xD;
          8. Reduced life expectancy in the short term due to non-cardiac disease&#xD;
&#xD;
          9. Simultaneous participation in another interventional trial&#xD;
&#xD;
         10. Pregnant or breastfeeding females&#xD;
&#xD;
         11. Known or suspected alcohol and/or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Seidler, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Goettingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfram-Hubertus Zimmermann, Prof.</last_name>
    <phone>+49 551 / 3965781</phone>
    <email>sekretariat.pharma@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Walker, Dr.</last_name>
    <phone>+49 551 / 3960825</phone>
    <email>florian.walker@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Seidler, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>North Rhine-Westphalia</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Gummert, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Ensminger, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Goettingen</investigator_affiliation>
    <investigator_full_name>Karsten Gavenis</investigator_full_name>
    <investigator_title>on behalf of Principal Investigator Prof. Seidler</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

